Health
Pancreatic cancer pill trial finds tumours undetectable in one in 12 patients
Coverage
2 reports · over 9 hours
A 61-patient trial of the daily pill daraxonrasib found tumours stopped growing in 90% of people with advanced pancreatic cancer, researchers reported in Barcelona.
- Cancer became undetectable on CT scans in about 8% of the 61 patients, all with advanced pancreatic cancer that had spread.
- Tumours stopped growing in 90% of participants and shrank or disappeared in just over 60%, over an average 18-month follow-up.
- 76.6% of patients were alive one year after starting treatment, against 40-45% of those given chemotherapy alone.
- Cancer Research UK said further trials are needed before the treatment can be assessed for use on the NHS.

